{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:15:05Z","timestamp":1715991305589},"reference-count":84,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pain Manag."],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.2217\/pmt-2018-0046","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T14:46:15Z","timestamp":1559141175000},"page":"297-306","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Opioid Maintenance, Weaning and Detoxification Techniques; Where We have been, Where We are Now and What the Future Holds: An Update"],"prefix":"10.1080","volume":"9","author":[{"given":"Anthony R","family":"Plunkett","sequence":"first","affiliation":[{"name":"Department of Anesthesia & Operative Services, Womack Army Medical Center Ft Bragg, NC28310, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M","family":"Peden","sequence":"additional","affiliation":[{"name":"Department of Anesthesia & Operative Services, Womack Army Medical Center Ft Bragg, NC28310, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"Centers for Disease Control and Prevention\n. CDC WONDER (2017). http:\/\/wonder.cdc.gov"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.131714"},{"key":"e_1_3_2_5_1","volume-title":"Improving the Quality of Pain Management Through Measurement and Action","author":"Berry P","year":"2003","unstructured":"Berry P , DahlJL , DonovanMIet al. Improving the Quality of Pain Management Through Measurement and Action. Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL, USA. (2003)."},{"key":"e_1_3_2_6_1","article-title":"Understanding the epidemic","author":"Centers for Disease Control and Prevention","year":"2017","unstructured":"Centers for Disease Control and Prevention . Understanding the epidemic. Opioid Overdose (2017). www.cdc.gov\/drugoverdose\/epidemic\/index.html","journal-title":"Opioid Overdose"},{"key":"e_1_3_2_7_1","article-title":"Drug overdose deaths in the United States, 1999\u20132016","author":"Hedegaard H","year":"2017","unstructured":"Hedegaard H , WarnerM , Mini\u00f1oAM. Drug overdose deaths in the United States, 1999\u20132016. Data Briefs (2017). www.cdc.gov\/nchs\/products\/databriefs\/db294.htm","journal-title":"Data Briefs"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_3_2_9_1","unstructured":"North Carolina General Assembly\n. Strengthen Opioid Misuse Prevention (STOP) Act overview. (2017). www.ncleg.net\/DocumentSites\/Committees\/NCCFTF\/Presentations\/2017-2018\/STOP%20Act%20Overview%20CFTF%209-26-2017.pdf"},{"key":"e_1_3_2_10_1","article-title":"Information about medication assisted treatment","author":"US FDA","year":"2018","unstructured":"US FDA . Information about medication assisted treatment. Drugs (2018). www.fda.gov\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm600092.htm","journal-title":"Drugs"},{"key":"e_1_3_2_11_1","article-title":"FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults","author":"Felberbaum M","year":"2018","unstructured":"Felberbaum M . FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults. FDA News Rel. (2018). www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm607884.htm","journal-title":"FDA News Rel."},{"key":"e_1_3_2_12_1","unstructured":"Lucemyra prescribing information. US Worldmeds KY USA (2018)."},{"key":"e_1_3_2_13_1","unstructured":"Electronic Code of Federal Regulations\n. Title 42: public health (2018). https:\/\/ecfr.io\/Title-42\/pt42.1.8#sp42.1.8.f"},{"key":"e_1_3_2_14_1","volume-title":"Federal Guidelines for Opioid Treatment Programs","author":"Smith NW","year":"2015","unstructured":"Smith NW . Federal Guidelines for Opioid Treatment Programs. Substance Abuse and Mental Health Services Administration, WA, DC, USA (2015)."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-008-9056-1"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(91)90182-O"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(93)90036-9"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2008.07.002"},{"key":"e_1_3_2_19_1","volume-title":"Bonica\u2019s Management of Pain","author":"Fishman SM","year":"2010","unstructured":"Fishman SM , BallantyneJC , RathmellJP. Bonica\u2019s Management of Pain (4) Fishman SM, Ballantyne JC, Rathmell JP (eds). Lippincott Williams & Wilkins, MD, USA. (2010).","edition":"4"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.05.004"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(01)00396-7"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.04.007"},{"key":"e_1_3_2_23_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (5)","year":"2013","unstructured":"Kupfer DJ, Reigier DA, Narrow WE, Schultz SK, Kuhl EA. Diagnostic and Statistical Manual of Mental Disorders (5). American Psychiatric Association, WA, DC, USA. (2013)."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.08.007"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5982-8"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.07.020"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00096-9"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2008.0035"},{"key":"e_1_3_2_29_1","first-page":"1201","volume-title":"Comprehensive Handbook of Drug and Alcohol Addiction","author":"Margolin A","year":"1991","unstructured":"Margolin A , KostenTR , MillerNS. Opioid detoxification and maintenance with blocking agents. In: Comprehensive Handbook of Drug and Alcohol Addiction..Taylor & Francis, London, UK, 1201\u20131212 (1991)."},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90215-9"},{"key":"e_1_3_2_31_1","volume-title":"Treating Drug Problems: A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems.","author":"Institute of Medicine (US)","year":"1990","unstructured":"Institute of Medicine (US) Committee for the substance abuse coverage study. In: Treating Drug Problems: A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems.National Academies Press, WA, DC, USA (1990)."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/713659366"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-197103000-00002"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2012.04.011"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011190"},{"issue":"5","key":"e_1_3_2_36_1","first-page":"347","article-title":"Methadone maintenance treatment (MMT): a review of historical and clinical issues","volume":"67","author":"Joseph H","year":"2000","unstructured":"Joseph H , StancliffS , LangrodJ. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt. Sinai J. Med.67(5-6), 347\u2013364 (2000).","journal-title":"Mt. Sinai J. Med."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"issue":"3","key":"e_1_3_2_38_1","first-page":"1","article-title":"Methadone maintenance at different dosages for opioid dependence","author":"Faggiano F","year":"2003","unstructured":"Faggiano F , Vigna-TagliantiF , VersinoE , LemmaP. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev. (3), 1\u201338 (2003).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01232.x"},{"key":"e_1_3_2_40_1","first-page":"1","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo L","year":"2017","unstructured":"Sordo L , BarrioG , BravoMJet al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ357, 1\u201314 (2017).","journal-title":"BMJ"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2016.09.003"},{"issue":"1","key":"e_1_3_2_42_1","first-page":"1","article-title":"Opioid prescribing: methadone risk mitigation","volume":"26","author":"Christie JM","year":"2011","unstructured":"Christie JM . Opioid prescribing: methadone risk mitigation. APSF Newsletter26(1), 1\u201315 (2011).","journal-title":"APSF Newsletter"},{"issue":"6","key":"e_1_3_2_43_1","first-page":"CD008939","article-title":"QTc interval screening for cardiac risk in methadone treatment of opioid dependence","author":"Pani PP","year":"2013","unstructured":"Pani PP , TroguE , MaremmaniI , PaciniM. QTc interval screening for cardiac risk in methadone treatment of opioid dependence. Cochrane Database Syst. Rev.6, CD008939 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000075"},{"key":"e_1_3_2_45_1","article-title":"Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest","volume":"2015","author":"Walton G","year":"2015","unstructured":"Walton G , NolanS , SutherlandC , AhamadK. Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest. BMJCase Rep.2015, bcr2015210239 (2015).","journal-title":"BMJCase Rep."},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.05.012"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00764.x"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.001128.x"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12440"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(81)90064-8"},{"issue":"2","key":"e_1_3_2_51_1","article-title":"LAAM maintenance vs methadone maintenance for heroin dependence","author":"Clark NC","year":"2002","unstructured":"Clark NC , LintzerisN , GijsbersAet al. LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database Syst. Rev. (2), CD002210. ( 2002).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_52_1","unstructured":"Kux L\n. Determination that ORLAAM (levomethadyl acetate hydrochloride) oral solution 10 milligrams\/milliliter was not withdrawn from sale for reasons of safety or effectiveness. US FDA WA DC USA (2011)."},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.147"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.3.4.477"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.7.1025"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.9344753.x"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.67"},{"issue":"2","key":"e_1_3_2_58_1","article-title":"Buprenorphine for managing opioid withdrawal","author":"Gowing L","year":"2017","unstructured":"Gowing L , AliR , WhiteJM , MbeweD. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst. Rev.2, CD002025 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70039-1"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01154.x"},{"issue":"2","key":"e_1_3_2_61_1","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick RP","year":"2014","unstructured":"Mattick RP , BreenC , KimberJ , DavoliM. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev.2, CD002207 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1604339"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12051"},{"key":"e_1_3_2_65_1","article-title":"FDA approves first buprenorphine implant for treatment of opioid dependence","author":"Peddicord S","year":"2016","unstructured":"Peddicord S . FDA approves first buprenorphine implant for treatment of opioid dependence. FDA News Rel. (2016). www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm503719.htm","journal-title":"FDA News Rel."},{"key":"e_1_3_2_66_1","author":"Titan Pharmaceuticals, Inc., Probuphine","year":"2018","unstructured":"Titan Pharmaceuticals, Inc., Probuphine . Product Pipeline (2018). www.titanpharm.com\/pipeline\/probuphine","journal-title":"Product Pipeline"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S109331"},{"key":"e_1_3_2_68_1","article-title":"FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opiod use disorder","author":"Felberbaum M","year":"2017","unstructured":"Felberbaum M . FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opiod use disorder. FDA News Rel. (2017). www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm587312.htm","journal-title":"FDA News Rel."},{"key":"e_1_3_2_69_1","unstructured":"Sublocade prescribing information. Indivior Inc. VA USA (2017)."},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S72543"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6712a1"},{"issue":"6","key":"e_1_3_2_72_1","first-page":"101","article-title":"Community-based opioid overdose prevention programs providing naloxone \u2013 United States, 2010","volume":"61","author":"Wheeler E","year":"2012","unstructured":"Wheeler E , DavidsonPJ , JonesTS , IrwinKS. Community-based opioid overdose prevention programs providing naloxone \u2013 United States, 2010. MMWR61(6), 101\u2013105 (2012).","journal-title":"MMWR"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-016-0323-x"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2015.05.022"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2008.136937"},{"key":"e_1_3_2_76_1","first-page":"1","article-title":"Long-acting injectable naltrexone for the management of patients with opioid dependence","volume":"5","author":"Kjome KL","year":"2011","unstructured":"Kjome KL , MoellerFG. Long-acting injectable naltrexone for the management of patients with opioid dependence. Subst. Abuse5, 1\u20139 (2011).","journal-title":"Subst. Abuse"},{"issue":"2","key":"e_1_3_2_77_1","article-title":"\u03b12\u2010adrenergic agonists for the management of opioid withdrawal","author":"Gowing L","year":"2016","unstructured":"Gowing L , FarrellM , AliR , WhiteJM. \u03b12\u2010adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst. Rev. (2), CD002024 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"e_1_3_2_78_1","article-title":"Opioid antagonists with minimal sedation for opioid withdrawal","author":"Gowing L","year":"2017","unstructured":"Gowing L , AliR , WhiteJM. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst. Rev. (5), CD002021 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199912000-00015"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977214409"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00100-8"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-100102407"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.8.903"},{"issue":"38","key":"e_1_3_2_84_1","first-page":"777","article-title":"Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification \u2013 New York City, 2012","volume":"62","author":"Berlin D","year":"2013","unstructured":"Berlin D , FarmerBM , RaoRBet al. Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification \u2013 New York City, 2012. MMWR62(38), 777\u2013780 (2013).","journal-title":"MMWR"},{"key":"e_1_3_2_85_1","volume-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence.","author":"Davoli M","year":"2009","unstructured":"Davoli M , FarrellM , FiellinDet al. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. WHO, Switzerland (2009)."},{"key":"e_1_3_2_86_1","volume-title":"Drug Misuse: Opiod Detoxification","author":"Gerada C","year":"2008","unstructured":"Gerada C , PillingS , BissettPet al. Drug Misuse: Opiod Detoxification. British Psychological Society, Leicester, UK (2008)."}],"container-title":["Pain Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pmt-2018-0046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:04:10Z","timestamp":1715954650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pmt-2018-0046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.2217\/pmt-2018-0046"],"URL":"https:\/\/doi.org\/10.2217\/pmt-2018-0046","relation":{},"ISSN":["1758-1869","1758-1877"],"issn-type":[{"value":"1758-1869","type":"print"},{"value":"1758-1877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}